Last Updated : January 8, 2025
Details
Generic Name:
teplizumab
Project Status:
Pending
Therapeutic Area:
Delay onset of Stage 3 Type 1 Diabetes
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Tzield
Project Line:
Reimbursement Review
Project Number:
SR0867-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The requested reimbursement criteria is for Tzield (teplizumab) to delay the onset of
Stage 3 Type 1 Diabetes in adult and pediatric patients 8 years of age and older with
Stage 2 Type 1 Diabetes.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The anticipated indication is to delay the onset of Stage 3 Type 1 Diabetes in adult and
pediatric patients 8 years of age and older with Stage 2 Type 1 Diabetes.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 8, 2025